
The coronavirus news this week focuses on the Pfizer-BioNTech vaccine, with clinical trial participants receiving the vaccine saying it created …

AstraZeneca’s Brilinta (ticagrelor) reduced the composite of stroke and death in patients with head and neck artery atherosclerosis who had …

Pfizer has filed a petition in a US court against Indian companies Dr Reddy’s Laboratories and Aurobindo Pharma that alleges …

Johnson & Johnson has said that it is injecting around $1 billion of funding into its research efforts to develop …

Pfizer is set to launch its first delivery programme for the COVID-19 vaccine it developed with BioNTech. It will be …

US firm Moderna has swooped in with Phase 3 interim data for its own messenger RNA (mRNA) vaccine candidate, mRNA-1273, …

The advent of an effective vaccine could mean a return to normalcy by next winter, argues Professor UÄŸur Åžahin, Professor …

Johnson & Johnson has kicked off a second global Phase 3 trial to assess the safety and efficacy of its …

The British Labour Party has called for the implementation of new legal measures to combat anti-vaccination campaigns on the internet …

The antidepressant fluvoxamine could treat COVID-19 patients and stop their symptoms from worsening, according to a new study.

The British Prime Minister Boris Johnson has begun working in self isolation after coming into contact with an MP who …

Israeli Health Minister Yuli Edelstein has confirmed the nation’s plans to strike an agreement with Pfizer to secure eight million …

Professor Guido Rasi, Executive Director at the European Medicines Agency (EMA), serves his final day at the European regulator today, …

India is aiming to have 100 million doses of AstraZeneca’s COVID-19 vaccine ready for an inoculation drive beginning next month. …

The World Health Organization announced today that it will set up the Global Centre for Traditional Medicine in India. General …

The top ten news stories this week focus on COVID-19 vaccines, with clinical trial participants who received the Pfizer/BioNTech coronavirus …

AstraZeneca’s Calquence has failed to improve survival rates and prevent lung failure in patients hospitalised with COVID-19. Calquence (acalabrutinib) is …

Sanofi’s Cablivi (caplacizumab) has received recommendation from NICE for routine NHS use in England and Wales for the treatment of …

With the news that Pfizer and BioNTech’s COVID-19 vaccine candidate demonstrated 90% efficacy in a Phase 3 interim analysis, it …

People who are infected with COVID-19 are at higher risk of developing depression, insomnia and anxiety for the first time, …